A Phase II Study of Neoadjuvant Transcatheter Arterial ChemoembolizationTACEPlus PD-1 Antibody (Tislelizumab) in the Locally Advanced Stomach Adenocarcinoma
Latest Information Update: 27 May 2024
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 21 May 2024 Planned primary completion date changed from 1 Jan 2023 to 1 Dec 2024.
- 28 Apr 2022 Status changed from not yet recruiting to recruiting.
- 28 Apr 2022 Planned End Date changed from 1 Mar 2025 to 1 Jan 2026.